Non-Alcoholic Fatty Liver Disease Trial, Recruiting (NCT04036357)

Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT04036357 Sponsor: University of Roma La Sapienza Condition: Non-Alcoholic Fatty Liver Disease

Printed from Voxsanity (voxsanity.com.au) — NCT04036357 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Non Alcoholic Fatty Liver Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years old or older
You have been diagnosed with at least one of the following conditions: obesity, diabetes, high blood pressure, or high cholesterol/fats in the blood

Who may not be able to join:

You drink more than a moderate amount of alcohol daily — specifically more than 20g per day for women or more than 30g per day for men (this will be measured using a standard questionnaire)
You have hepatitis B or hepatitis C infections
You have tested positive for autoimmune hepatitis (a condition where the immune system attacks the liver)
You have cirrhosis (severe liver scarring) or another long-term liver disease
You have been diagnosed with any form of cancer
You are taking certain medications known to cause fat build-up in the liver, such as amiodarone (a heart medication)
You have another long-term infectious or autoimmune disease (a condition where the immune system attacks the body)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Maria Del Ben, MD, University of Roma La Sapienza

Phone: +390649972249

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04036357

Sponsor: University of Roma La Sapienza

Phase: Not Applicable

Status: Recruiting

Condition: Non-Alcoholic Fatty Liver Disease

Trial contact: +390649972249

More information: https://clinicaltrials.gov/study/NCT04036357

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years old or older
You have been diagnosed with at least one of the following conditions: obesity, diabetes, high blood pressure, or high cholesterol/fats in the blood

Who may not be able to join:

You drink more than a moderate amount of alcohol daily — specifically more than 20g per day for women or more than 30g per day for men (this will be measured using a standard questionnaire)
You have hepatitis B or hepatitis C infections
You have tested positive for autoimmune hepatitis (a condition where the immune system attacks the liver)
You have cirrhosis (severe liver scarring) or another long-term liver disease
You have been diagnosed with any form of cancer
You are taking certain medications known to cause fat build-up in the liver, such as amiodarone (a heart medication)
You have another long-term infectious or autoimmune disease (a condition where the immune system attacks the body)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Roma La Sapienza

Registry

ClinicalTrials.gov

Start date

1 November 2011

Est. completion

31 December 2036

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Clinical, biochemical and genetic factors associated to progression of liver fibrosis in a large cohort of patients with NAFLD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov